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1.1 Background   
Tuberculosis (TB) remains a major global public health problem and it persists as a major 
cause of human mortality and morbidity, affecting almost a third of the world’s population 
[Sudre et al., 1992; WHO 2002]. There were 9.2 million new cases of tuberculosis worldwide 
in 2006, with the highest rates of disease in African countries. Despite efforts to control 
tuberculosis and reduce the rate of infections, the lack of accurate laboratory diagnosis 
hinders these efforts. The rapid spread of the human immunodeficiency virus (HIV) in sub-
Saharan African countries has led to dramatic rises in incidence of TB cases and has been 
associated with worsening treatment outcomes, even in well functioning TB programmes 
[Raviglione et al., 1997]. The impact of the HIV epidemic on tuberculosis depends on the 
degree of overlap between the population infected with HIV and that infected with 
Mycobacterium tuberculosis. In sub-Saharan Africa the prevalence of both infections is high 
with considerable overlap between the infected populations, since the age distribution of 
both infections is concentrated in the 20-50-year age group. In 1994 there were an estimated 
4.8 million people worldwide infected with both M. tuberculosis and HIV, of whom over 
75% were reported to be living in sub-Saharan Africa (6). Worldwide estimates of the 
proportions of new tuberculosis cases attributable to HIV infection were 4% in 1990, 8% in 
1995, projected to 14% by the year 2000 [WHO 2002]. HIV-related infection thus accounts for 
a relatively small but increasing proportion of the global tuberculosis burden. In sub-
Saharan Africa, however, it accounts for a greater part of the burden: an estimated 30% or 
more of tuberculosis cases by the year 2000 [WHO 2002]. THE WORLD HEALTH 
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ORGANIZATION (WHO) estimated that both the number of cases of tuberculosis 
worldwide and the percentage attributable to coexisting HIV infection would increase 
substantially during the decade between 1990 and 2000 [WHO 2002]. Furthermore, most of 
this burden occurs among the low-income countries of the world, particularly those in sub-
Saharan Africa, the region most heavily affected since the beginning of the HIV 
epidemic[Sudre et al., 1992]. 
Although both culture techniques and the introduction of nucleic acid-based tests can 
improve laboratory diagnosis [Perkins and Cunningham, 2007], these procedures are not 
widely available in most low-income countries. Instead, in most low income countries, the 
diagnosis of pulmonary tuberculosis (PT) still relies on the search for Acid-Fast Bacilli (AFB) 
in sputum smears, which has sensitivity between 50 and 80% in well-equipped laboratories 
[Aber et al., 1980]. In low-income countries, poor access to high-quality microscopy services 
contributes to even lower rates of AFB detection. Furthermore, in countries with high 
prevalence of both pulmonary tuberculosis and HIV infection, the detection rate is even 
lower owing to the paucibacillary nature of pulmonary tuberculosis in patients with HIV 
infection. In fact, HIV changes the presentation of smear-negative pulmonary tuberculosis 
from a slowly progressive disease with low bacterial load and reasonable prognosis, to 
one with reduced pulmonary cavity formation and sputum bacillary load, more frequent 
involvement of the lower lobes, and an exceptionally high mortality rate [Hopewell, 1992; 
Jones et al., 1993]. This means that there are many cases of PT that are not going to be 
diagnosed by this test, and they are denominated smear-negative pulmonary tuberculosis 
(SNPT). Therefore, it is often necessary to make a clinico-radiological diagnosis of smear-
negative TB using an algorithm and to initiate empirical TB treatment while awaiting 
culture results. Therefore, early identification of persons who have TB, whether smear 
positive or smear negative, is desirable both to enable appropriate isolation procedures 
and to provide a basis for early institution of therapy. Conversely, correct prediction of 
persons who are unlikely to have TB is important as well to limit the expense and 
potential toxicity of empiric therapy. A clinical prediction rule (CPR) is defined as a 
"decision making tool for clinicians that includes three or more variables obtained from 
the history, or physical examination of the patient, or from simple diagnostic tests and 
that either provides the probability of an outcome or suggest a diagnostic or therapeutic 
course of action. Given the lack of resources to use sophisticated laboratory tests for this 
problem in most developing countries, we will try to develop a CPR to diagnose Smear-
negative pulmonary tuberculosis.  
The primary objective of this chapter will be to conduct a systematic review of the literature 
to gather data on evaluation of various criteria, algorithms, and clinical indicators used in 
low-income countries in the diagnosis of PT in people with suspected tuberculosis but 
repeated negative sputum smears with particular consideration of HIV infection or AIDS. 
This review will be of help therefore to develop it in the format of a score based on simple 
clinical variables for the diagnosis of Smear-negative pulmonary tuberculosis. 
This article will describe the incidence, natural history and differential diagnoses of smear-
negative pulmonary TB in HIV negative and HIV-positive patients. The various strategies 
that have attempted to address smear-negative TB will then be reviewed; highlighting 
plausible interventions for developing countries and areas for future research. 
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1.2 Definition of smear-negative pulmonary tuberculosis 
Smear-negative tuberculosis is currently defined as symptomatic illness in a patient with at 
least two sputum smear examinations negative for AFB on different occasions in whom 
pulmonary tuberculosis is later confirmed by culture, biopsy, or other investigations[WHO 
2007].  Guidelines from some developing countries like Malawi through their national 
Tuberculosis Program recommends that the diagnosis of smear negative TB be based on 
four criteria of (i) cough for more than 3 weeks, (ii) three sputum smears negative for AFB, 
(iii) no response to an antibiotic, and (iv) a chest x-ray compatible with TB[Hargreaves et al., 
2000].   
The following are suggested case definitions for use in HIV-prevalent settings[WHO 2007]  
Smear-Positive Pulmonary Tuberculosis 
 One sputum smear examination positive for AFB and  
 Laboratory confirmation of HIV infection or  
 Strong clinical evidence of HIV infection*  
Smear-Negative Pulmonary Tuberculosis 
 At least two sputum specimens negative for AFB and  
 Radiographical abnormalities consistent with active tuberculosis and  
 Laboratory confirmation of HIV infection or  
 Strong clinical evidence of HIV infection* and  
 Decision by a clinician to treat with a full course of antituberculosis chemotherapy  
OR 
 A patient with AFB smear-negative sputum which is culture-positive for Mycobacterium 
tuberculosis  
1.3 Impact of HIV on TB infection 
Persons with HIV-1 infection are at increased risk of active TB due to reactivation of latent 
TB and more rapid progression to disease after TB infection. It is well known that the risk of 
TB is greatly increased in HIV-infected persons, and some of the underlying mechanisms are 
being elucidated. Effective immunity to TB involves coordination of responses between the 
innate and adaptive immune systems, both of which are altered by HIV[Patel and Koziel, 
2009].  The strongest risk factor for developing TB disease in HIV lies in helper T-cell type 1 
(Th1) adaptive immunity, specifically the progressive decline in CD4 T-cell count associated 
with advanced HIV [Williams and Dye, 2003]. In patients with prior TB exposure as 
assessed by a positive Purified protein derivative (PPD) response, the incidence of TB is 
2.6%/year for those with a CD4 T-cell count greater than 350/ml, 6.5%/year for those with 
aCD4 T-cell count from 200 to 350/ml, and 13.3%/year for those with a CD4 T-cell count 
less than 200/ml [Antonucci et al., 1995]. With decline of the CD4 T-cell count, there is also a 
higher risk of anergy to skin test reactions, suggesting dysfunction of delayed-type 
hypersensitivity dependent on Th1-type immunity [Markowitz et al., 1993]. There is also in 
vitro evidence for qualitative dysfunction of CD4 T cells in HIV. Compared with TB-infected 
patients without HIV infection, peripheral blood mononuclear cells from patients coinfected 
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with HIV and TB have decreased proliferative T-cell responses and reduced IFN-g 
production to Mycobacterium tuberculosis in vitro, whereas anti-inflammatory IL-10 
production is preserved [Zhang et al., 1994]. However, the observation that TB incidence 
increases shortly after HIV seroconversion, and before reduction in peripheral blood CD4 T-
cell counts [Sonnenberg et al., 2005], suggests that HIV confers additional mechanisms of 
susceptibility to TB infection. Investigations into the progression of primary HIV infection to 
AIDS suggest that primary HIV infection is associated with a precipitous decrease in 
mucosal CD4 memory T cells [Brenchley et al., 2006a], which may set the stage for chronic 
immune activation and CD4 T-cell depletion through mucosal translocation of bacteria 
through the gut [Brenchley et al., 2006b]. Thus, mucosal CD4 memory T-cell depletion may 
provide a potential mechanism to account for disrupted T-cell function in early HIV 
infection, although whether similar events occur in the lung mucosa has not yet been 
established [Brenchley et al., 2008]. Indeed, primary HIV infection is associated with 
decreased PPD-specific IFN-secreting T cells [Sutherland et al., 2006; Geldmacher et al., 
2008] and ESAT (early secreted antigenic target)-6–specific T cells [Geldmacher et al., 2008] 
in the blood, suggesting that early depletion of memory T cells may affect specific immunity 
to TB. Lung lavage enzymelinked immunospot (ELISPOT) studies also suggest decreased 
bacillus Calmette-Gue´rin (BCG)– or PPD-specific pulmonary CD4 T cells in asymptomatic 
HIV-infected persons compared with HIV-negative persons [Kalsdorf et al., 2009]. HIV–TB 
coinfection may also be associated with increased serum levels of IL-4, an anti-Th1 type 
cytokine that hinders immune response to MTb [Dheda et al., 2005]. Interestingly, alveolar 
lavage cells from coinfected individuals may have intact ability to secrete IFN-g in response 
to MTb antigens in vitro [Dheda et al., 2005], although this may not translate to equivalent 
cell function and cell numbers in vivo. 
Independent of CD4 T-cell count, HIV also affects the function of innate immune cells, 
especially alveolar macrophages (AMs), which serve as the main reservoir for MTb infection 
[Russell, 2001; Dheda et al., 2009]. MTb has evolved to persist within macrophages in part 
through prevention of MTb phagosomal fusion with lysosomes, thus preventing 
intracellular killing of MTb [Brown et al., 1969; Mwandumba et al., 2004]. AMs can combat 
intracellular parasitization by releasing immune-activating cytokines or chemokines, and by 
programmed cell death or apoptosis [Oddo et al., 1998; Keane et al., 2000]. Apoptosis 
benefits the host by promoting intracellular killing of MTb [Oddo et al., 1998; Keane et al., 
2000] and improving antigen presentation by additional phagocytes to activate adaptive 
immunity [Schaible et al., 2003; Winau et al., 2006]. Whereas asymptomatic HIV infection 
does not affect the intracellular growth of MTb [Day et al., 2004; Kalsdorf et al., 2009], AMs 
from asymptomatic HIV-infected subjects have increased phagocytosis of MTb [Day et al., 
2004; Patel et al., 2007], decreased release of specific cytokines and chemokines [Saukkonen 
et al., 2002], and similarly impaired MTb phagosomal maturation [Mwandumba et al., 2004] 
compared with AMs from healthy subjects. AMs from HIV-infected subjects also have 
decreased apoptosis in response to MTb [Patel et al., 2007]; the mechanism may involve 
increased lung levels of IL-10 in HIV, which up-regulates BCL-3 (B-cell lymphoma 3–
encoded protein), an apoptosis inhibitor [Patel et al., 2009]. HIV infection of macrophages 
also inhibits autophagy [Kyei et al., 2009], another cellular process that may be critical for 
macrophage intracellular killing of MTb [Gutierrez et al., 2004]. 
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The focus of this chapter is on sub-Saharan Africa (SSA). Countries in the developing world 
and especially in sub-Saharan Africa are the most affected by the TB epidemic. Worldwide, 
in 2008, the estimated global TB incidence rate was 139 cases per 100,000 population, which 
equates to 9.4 million (range, 8.9–9.9 million) incident TB cases. This represents an 11% 
increase in TB incidence rate and a 40% increase in the number of TB cases, compared with 
estimates from 1990[WHO 2009]. This global increase in rates was attributable to increases 
in the SSA and was mainly driven by the HIV epidemic. Particularly in SSA, mirroring the 
HIV epidemic, TB incidence and TB-associated death rates have doubled, and the number of 
TB cases and TB-related deaths has tripled in comparison with estimated figures from 
1990[WHO 2009]. The HIV epidemic has fuelled the tuberculosis epidemic in the region. Of 
the 9.4 million incident cases in 2009, an estimated 1.0–1.2 million (11–13%) were  
HIV-positive, with a best estimate of 1.1 million (12%). Of these HIV-positive TB  
cases, approximately 80% were in the African Region 
(http://www.who.int/tb/publications/global_report/2010/). The relative risk of 
developing TB in HIV-positive individuals, compared with HIV-negative individuals, is 21 
in high HIV prevalence countries and 37 in low HIV prevalence countries[WHO 2009]. 
Moreover, these co-infected people have at least a 30% lifetime risk of developing active 
tuberculosis, thus contributing to the increase in the number of tuberculosis cases in the 
region. In Africa, TB is often the first manifestation of HIV infection, and accounts for a 
disproportionate burden of morbidity and mortality in co-infected patients [Munyati et al., 
2005].  
As a consequence, HIV is the single most significant risk factor for the development of TB, 
and HIV patients are at increased risk for primary and reactivation disease, as well as 
exogenous reinfection [Sonnenberg et al., 2001]. The risk of death in co-infected patients is 
two to four times that of HIV individuals without TB, independent of CD4 count [Whalen et 
al., 1995; Connolly et al., 1999]. In addition, coinfected patients have a markedly greater risk 
of progression to AIDS compared with HIV patients without TB [Whalen et al., 1997]. The 
focus of this chapter is therefore sub-Saharan Africa, the region of the world most severely 
affected by the HIV/TB co-epidemic.  
2. Search strategy 
We used a combination of systematic review, document analysis, and global expert opinion 
to prepare this chapter. We identified relevant publications by searches of Medline, 
PubMed, Embase, HealthSTAR, and Web of Science with the keywords: “tuberculosis”, 
“Mycobacterium tuberculosis”, “sputum negative”, “smear negative”, AFB negative”, 
“negative for AFB”, “HIV”  ,  “diagnosis” and “treatment” for papers published in English 
between 1990 and December, 2010. Studies were included in the review if they reported on 
tuberculous disease in people with HIV infection or AIDS in sub- Saharan Africa and if the 
disease had been stratified into smear-positive and smear-negative. We reviewed data for 
smear-negative pulmonary tuberculosis only for patients who were also HIV positive. All 
retrieved titles and abstracts were scrutinised for the relevance to the topic. Analytical 
studies that identified demographic, clinical, radiological, or simple laboratory based 
indicators facilitating the diagnosis of smear-negative tuberculosis were included. An 
assessment of methodological quality was undertaken for each paper. 
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We used the WHO definition of a case of smear-negative pulmonary tuberculosis: at least 
two sputum specimens negative for acid-fast bacilli, abnormalities on radiography 
consistent with active tuberculosis, no response to broad-spectrum antibiotics, and a 
decision by a clinician to treat with a full course of antituberculosis chemotherapy. 
3. Frequency of smear-negative pulmonary tuberculosis 
Given the immunopathological spectrum seen in HIV-infected TB patients, it would be 
expected that the proportion of patients with smear-negative PT should increase in areas 
where the prevalence of HIV is high. Initial impressions were that HIV infection in sub-
Saharan Africa was associated with a large and predominant increase in smear-negative PT 
[Harries, 1990]. It is apparent from cross-sectional studies, however, that the majority of 
HIV-positive PT patients are smear positive, although the proportion of smear-negative 
patients is greater among those infected with HIV than among those who are HIV-negative 
[Elliott et al., 1990; Nunn et al., 1992]. Since the advent of HIV, the annual incidence of TB 
has more than doubled in some African countries [De Cock et al., 1992; Wilkinson and 
Davies, 1997], and there has been a disproportionate increase in the reported rate of smear-
negative disease. A study in Zambia [Elliott et al., 1993] of over 100 patients with culture-
positive PT found that 24% of those who were HIV-seronegative had a negative sputum 
smear, compared with 43% of those who were HIV-seropositive. With good routine 
reporting systems, the national tuberculosis programmes of countries such as Malawi and 
the United Republic of Tanzania have reported a larger increase in new cases of smear 
negative than of smear-positive PT in the last 10 years [Graf 1994].   
Other studies showed that the proportion of cases of smear-negative pulmonary 
tuberculosis in HIV-positive tuberculosis patients ranged from 10% to 61% [Affolabi et al., ; 
Long et al., 1991; Elliott et al., 1993; Harries et al., 1997; Behr et al., 1999; Bruchfeld et al., 
2002; Zachariah et al., 2003; Kang'ombe et al., 2004; Yassin et al., 2004; Chintu and Mwaba, 
2005]. The apparent variation in the incidence of negative sputum smear between these 
studies may be due to differences in the study populations. Some studies were conducted 
among patients seen at specialist institution-based centres who may be more or less likely to 
be smear-positive depending on the referral procedure. The level of immunosuppression 
among the HIV-positive patients in the various studies may also have differed. Less severely 
immunocompromised HIV-positive patients tend to have classic cavitary TB which is 
smear-positive [De Cock et al., 1992; Desta et al., 2009]. As the level of immunocompromise 
increases with advancing HIV disease, atypical pulmonary features predominate and smear 
examinations prove less sensitive It is not clear at present whether these figures reflect the 
true pattern of PT or whether there is an over diagnosis or under diagnosis of smear-
negative cases. Reports from national tuberculosis programmes of the pattern of PT are 
influenced by various factors such as the criteria used to diagnose smear-negative PT, the 
extent to which these criteria are followed in clinical practice, and the number of other 
respiratory diseases that can resemble and be misdiagnosed as PT. Moreover, access to 
health services and DOTS in most resource-constrained settings with high HIV infection 
rates is restricted and services reach only a fraction of the population. If the availability of 
these services were increased, we expect that a much higher frequency of disease would be 
seen. Negative smears could also be the result of poor quality smear microscopy from 
inadequate sputum collection, storage, and staining, reading errors, or poor laboratory 
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services. In children, the diagnosis of pulmonary tuberculosis is especially difficult because 
the disease is paucibacillary and collection of sufficient sputum for smear microscopy and 
culture is difficult [Chintu and Mwaba, 2005]. HIV-positive patients with smear-negative 
tuberculosis are more likely to die during or before diagnosis than HIV-negative patients 
because of their immunosuppression, which leads to further under estimates of the 
magnitude of the problem. 
4. Transmission of tuberculosis from smear negative patients 
TB patients whose sputum smears are AFB negative are generally regarded as less infectious 
than those whose smears are positive. The relative TB transmission rate among patients with 
smear-negative, culture-positive pulmonary disease, compared with patients with smear-
positive disease, was found to be 0.24 in cohort study in the Netherlands [Tostmann et al., 
2008].  Overall, 17% of TB transmission events were attributable to source patients with 
sputum smear-negative, culture-positive disease [Tostmann et al., 2008]. These important 
findings are consistent with report from similar studies from San Francisco, California, and 
Vancouver, British Columbia [Behr et al., 1999; Hernandez-Garduno et al., 2004], collectively 
showing that in high-income countries, 10%–20% of TB transmission at the population level 
is attributable to source cases with smear-negative pulmonary TB. Tostmann and co-worker 
[Tostmann et al., 2008] speculated on the relevance of their data for countries in which HIV 
infection is endemic and rates of smear-negative TB disease are high. In these countries with 
a high incidence of TB, microscopic examination of sputum smear samples is often the only 
available diagnostic test for TB. As a result, patients with smear-negative TB do not receive a 
diagnosis in a timely manner; thus, disease may further develop, initiation of treatment may 
be delayed, and further TB transmission may occur [Siddiqi et al., 2003]. In view of these 
observations, one can conclude that transmission attributable to smear-negative pulmonary 
TB cases at the community level may be important in these regions. 
Whether this is true for HIV-positive patients with pulmonary tuberculosis remains to be 
established. One study from Zambia concluded that patients with HIV-associated 
pulmonary tuberculosis were less infectious than seronegative patients [Elliott et al., 1993], 
whereas results from Zaire showed no difference in rates of infection among household 
contacts [Klausner et al., 1993].  Moreover, In sub-Saharan Africa, HIV infection has had a 
devastating impact on TB control [Lawn et al., 2006; WHO 2009].  In a study of a community 
in a township in Cape Town, South Africa, for example, the antenatal HIV seroprevalence 
rate is 30%, and the annual TB notification rate has increased to 11500 cases per 100,000 
population [Lawn et al., 2006] almost 200-fold higher than TB rates in The Netherlands.  This 
has been associated with a major and disproportionate increase in the rate of smear-negative 
disease among HIV-infected individuals [Lawn et al., 2006].  
5. Diagnosis of smear negative TB in Sub-Saharan African 
In the absence of rapid and simple tools to diagnose tuberculosis, health institutions should 
avail guidelines or algorithms to assist clinical decision-making in HIV-prevalent and 
resource-constrained settings, to expedite the diagnostic process and minimize incorrect 
diagnosis and mortality. As much as possible, patients should be correctly diagnosed and 
treated for smear-negative pulmonary tuberculosis; however, treatment of those without the 
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disease should be avoided. The diagnosis of PT in adults in most African countries is based 
on simple techniques such as clinical assessment, sputum smear microscopy and chest 
radiography. Although specificity is high [Hargreaves et al., 2001; van Cleeff et al., 2003; 
Apers et al., 2004], major concerns include low sensitivity [Harries et al., 1997; Hargreaves et 
al., 2001] and delayed diagnosis of smear-negative disease [Harries et al., 1997; Colebunders 
and Bastian, 2000]. The accuracy of both microscopy and radiography is reduced by HIV, 
and so assessment of diagnostic approaches with existing methods and continuing research 
into new diagnostics are necessary [Colebunders and Bastian, 2000; Kivihya-Ndugga et al., 
2003; Angeby et al., 2004].  
Tuberculin skin testing in adults is not useful for individual diagnosis in populations with a 
high prevalence of M. tuberculosis infection. In addition, for HIV-infected individuals, there 
is the problem that cutaneous anergy increases as the CD4 lymphocyte count declines. In 
Zaire, over 50% of HIV-positive PT patients with a CD4 lymphocyte count <200/4l had a 
negative tuberculin skin test [Mukadi et al., 1993].  Techniques that are widely available in 
industrialized countries for obtaining pulmonary specimens (such as induced sputum and 
fibre-optic bronchoscopy with bronchoalveolar lavage) and for analysing them (such as 
culture, antigen detection and polymerase chain reaction) are beyond the resources of most 
hospitals in sub-Saharan Africa. 
5.1 Criteria used to diagnose smear-negative TB 
5.1.1 Clinical criteria 
Smear-negative tuberculosis is found to be more common in older than younger patients in 
a country with low prevalence of HIV infection [Samb et al., 1999].  However, countries with 
high HIV prevalence have an even age distribution, probably because HIV affects younger 
age-groups [Parry, 1993].  HIV is also more common in patients with smear-negative 
tuberculosis than in those with smear-positive disease. As for clinical indicators, pulmonary 
TB remains the most frequent form of active TB in HIV-1 infected persons, even those with 
low CD4 counts. Although the clinical presentation of pulmonary TB is different to the 
presentation of pulmonary TB in HIV-1 uninfected patients, the most common symptoms 
remain cough, fever, night sweats and significant weight loss [Batungwanayo et al., 1992; 
Bruchfeld et al., 2002].  Relative to HIV-1 uninfected patients, weight loss and fever are more 
common, whereas haemoptysis is less common and some studies have reported a decreased 
proportion of patients with cough [Selwyn et al., 1998; Kassu et al., 2007].  Although HIV-
infected persons with TB may have the classic symptoms of TB (eg, productive cough, chest 
pain, shortness of breath, hemoptysis, fever, night sweats, and/or weight loss), many such 
patients have few symptoms or have symptoms that are even less specific than those 
mentioned. Cough persisting for longer than 3 weeks warrants AFB microscopy, according 
to the current WHO guidance. However, one study, in an area of high HIV and tuberculosis 
prevalence, confirmed smear-negative tuberculosis in 35% of patients with cough 
unresponsive to antibiotics of only 1–3 weeks duration [Banda et al., 1998]. Most of these 
patients had atypical changes on chest radiography. That study suggests that pulmonary 
tuberculosis should be considered in patients with short duration of cough associated with 
weight loss and lack of response to antibiotics, particularly those who live in overcrowded 
places in areas with high prevalence of HIV infection and tuberculosis. It has been noted 
recently that a small proportion of HIV infected patients with TB are minimally 
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symptomatic or asymptomatic, particularly in developing countries with a high burden of 
both HIV infection and TB [Bassett et al., 2009; Edwards et al., 2009].   
A number of studies in Africa have tried to identify frequently occurring clinical features in 
smear-negative tuberculosis in areas with high prevalence of HIV infection and tuberculosis. 
A study, in Tanzania and Burundi, identified four clinical criteria for diagnosis of smear-
negative tuberculosis [Samb et al., 1997]: presence of cough for longer than 21 days (odds 
ratio 5·43[1·95–15·1]); presence of chest pain for longer than 15 days (1·98 [0·77–5·12]); 
absence of expectoration (odds ratio for expectoration 0·42 [0·15–1·18]); and absence of 
shortness of breath (odds ratio for breathlessness 0·26 [0·01–0·66]). Diagnosis of smear 
negative tuberculosis by any two of these criteria exhibited high sensitivity but low 
specificity (sensitivity 85%, specificity 67%, positive predictive value 43%, and negative 
predictive value 94%). When three of the criteria were considered, the specificity improved 
while the sensitivity decreased (sensitivity 49%, specificity 86%, positive predictive value 
50%, and negative predictive value 86%). The gold standard against which these clinical 
indicators were evaluated was Sputum culture, tissue histology, and positive clinical and 
radiological response to the antituberculosis therapy. However, patients with chronic lung 
disorders were excluded from the study, which limits the extent to which it can be 
generalised. The prevalence of HIV was high (71%) in both case and control groups.  
In another hospital-based study in Ethiopia, the most frequent symptoms in patients with 
pulmonary tuberculosis (both smear positive and smear negative) than in those without 
pulmonary tuberculosis were loss of appetite, weight loss, fever, night sweats, chest pain, 
haemoptysis, and breathlessness were more common [Tessema et al., 2001]. However, 
patients with smear-negative tuberculosis had night sweats for a longer time. Smear-
positive patients were more likely to have fever and weight loss than the smear negative 
group (odds ratios 4·1 [1·2–15·0] and 6·4 [2·3–17·8], respectively). The diagnosis by a group 
of tuberculosis physicians, which may have been due to lack of resources, although the 
authors do not clarify the reason in the paper, was used as the gold standard for diagnosis 
of pulmonary tuberculosis. However, in an area with low prevalence of HIV infection and 
high prevalence of tuberculosis, one study based in Senegal found no clinical features 
differentiating smear-negative from smear-positive tuberculosis other than the absence of 
cough (odds ratio 10·0 [1·96–50·0]) [Samb et al., 1997]. Limitations of this study were that it 
had a small sample size and that the diagnosis was confirmed by means of sputum culture 
in only 20% of cases. The overall prevalence of HIV in both case and control groups was 
8·9%. Our search could only retrieve one study that included subjects from a population 
with low prevalence of both HIV infection and tuberculosis [Kanaya et al., 2001].  Cough 
with expectoration was considered as a negative predictor of smear-negative tuberculosis 
(odds ratio 0·3 [0·1–0·6]). This study could not identify any other differentiating clinical 
features, possibly owing to the small sample size. 
5.1.2 Radiographic criteria 
Although the classical radiographic hallmarks of PT are cavitation, apical distribution, 
bilateral distribution, pulmonary fibrosis, shrinkage and calcification, no pattern is 
absolutely diagnostic of tuberculosis. Interpretation of chest X-rays of individuals suspected 
to have PT is difficult. In the pre-HIV era, there was considerable inter- and intra-observer 
variation in chest X-ray interpretation by radiologists and chest physicians [Thoman 1979]. 
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In sub-Saharan Africa with limited microbiological services, the problem is compounded 
because there are few trained radiologists or chest physicians, and in most district hospitals 
chest X-rays are interpreted by relatively inexperienced medical officers or paramedics., 
survey in Malawi showed that medical officers misdiagnosed a third of clinical vignettes, 
which described typical radiographic signs of tuberculosis [Nyirenda et al., 1999]. The 
nonspecific findings of pulmonary infiltrates, in the middle or lower lobes, in HIV positive 
PT patients adds to the difficulties of correct radiographic diagnosis. It is now well 
recognized in industrialized countries [Pedro-Botet et al., 1992; Greenberg et al., 1994] and 
countries in sub-Saharan Africa [Simooya et al., 1991; Abouya et al., 1995] that the chest X-
ray can appear normal in HIV-positive PT patients. 
Studies in sub-Saharan Africa revealed that tuberculous patients with HIV infection are 
more likely to have atypical chest radiographic appearances (pulmonary infiltrates with no 
cavities, lower-lobe involvement, intrathoracic lymphadenopathy, and even normal 
appearance) than tuberculous patients without HIV infection [Harries et al., 1998b; Banda et 
al., 2000]. In areas of high HIV and tuberculosis prevalence, 75% of patients with smear-
negative tuberculosis are likely to have atypical chest radiographic findings [Tessema et al., 
2001]. Patients with smear-negative tuberculosis are less likely to have cavities on the chest 
radiograph (odds ratio 2·56) than patients with smear positive tuberculosis [Samb et al., 
1999]. In addition, smear-negative patients can also present with normal or only slightly 
abnormal chest radiographs [Harries et al., 1998a]. A study confirmed pulmonary 
tuberculosis by sputum culture in 21% of patients with suspected tuberculosis and negative 
smears and normal or slightly abnormal chest radiographs. 47% of such patients were found 
to have typical radiographic features after 3 months. A third of the culture-negative patients 
also developed typical radiographic signs of tuberculosis during follow-up. Authors from 
that study suggested that close monitoring of smear-negative patients with suspected 
tuberculosis and normal or slightly abnormal chest radiographs is useful in areas with high 
prevalence of HIV infection and tuberculosis. 
5.1.3 Sputum smear microscopy 
Microscopy for the detection of AFB is rapid, low cost, and detects the most infectious cases 
of tuberculosis, but needs maintenance of equipment, consistent supply of reagents, and 
proper training in interpretation of the slides [Foulds and O'Brien, 1998].  International 
guidelines recommend the microscopic examination of three serial sputum specimens for 
acid-fast bacilli (AFB) in the investigation of pulmonary TB suspects, and define a positive 
case as a case with at least two smear-positive results [WHO 2003]. Recent studies have 
shown that under routine conditions, evaluating TB suspects with two sputum smears is as 
effective as with three sputum smears and is accompanied with less laboratory work and 
thus reductions in the cost related to the TB workup [Ipuge et al., 1996; Gopi et al., 2004]. 
This strategy could leave more time for the examination of each slide, should the workload 
dictate a reduction in the number of examinations. For a smear to be positive, there must be 
at least 5000-10 000 acid-fast bacilli per mL sputum, but these bacilli could be released only 
intermittently from cavities [WHO 2004].  If the sensitivity of smear microscopy could be 
improved, it would be a valuable instrument for TB control [Angeby et al., 2004] and would 
improve the diagnosis of tuberculosis in both adults. Many investigators have suggested 
sputum liquefaction and concentration through centrifugation to improve detection of AFB 
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in negative smears through direct microscopy. Liquefaction of sputum with sodium 
hypochlorite and concentration by either centrifugation or sedimentation is the most widely 
studied procedure [Angeby et al., 2004]. Studies carried out in developing countries have 
shown an increase of almost two fold in the sensitivity of AFB detection compared with 
direct microscopy [Gebre et al., 1995; Habeenzu et al., 1998]. A systematic review also 
showed that studies that used sputum processing with chemicals including bleach and 
centrifugation yielded a mean 18% increase in sensitivity and an incremental yield (positives 
with bleach minus positives with Ziehl-Neelsen stain only) of 9% [Steingart et al., 2006]. 
Specificity ranged from 96% to 100% with the bleach method alone and from 95% to 100% 
with the Ziehl-Neelsen method alone [Angeby et al., 2004]. In HIV-positive patients, 
sensitivity increased from 38·5% to 50·0% after concentration [Bruchfeld et al., 2000]. This 
improvement was less remarkable when compared with the sensitivity of direct microscopy 
supported by clinicians’ judgment in diagnosing pulmonary tuberculosis. The main 
disadvantages of the bleach method are the additional processing time, the technique lacks 
standardisation, and its advantages over other sputum concentration methods are not clear 
[Colebunders and Bastian, 2000].  
Fluorescence microscopy increases the probability of detecting AFB, especially if the sputum 
contains few bacteria, and hence improves the sensitivity of microscopy in HIV-positive 
patients. A systematic review of studies that used fluorescence microscopy showed that on 
average, in comparison with Ziehl-Neelsen microscopy, fluorescence microscopy showed a 
10% increase in sensitivity and 9% incremental yield, and this improvement was not affected 
by HIV status [Kivihya-Ndugga et al., 2003; Steingart et al., 2006].  The methods had similar 
specificity, but fluorescence microscopy done on one or two specimens was more cost 
effective than the Ziehl-Neelsen method used on three sputum specimens [Kivihya-Ndugga 
et al., 2003]. 
6. Differential diagnosis of smear-negative TB 
There have been a number of research studies in sub-Saharan Africa, using either induced 
sputum or fibre-optic bronchoscopy with bronchoalveolar lavage and transbronchial biopsy, 
to determine the range of pulmonary diseases found in patients with respiratory illness and 
negative AFB sputum smears. AFB microscopy lacks sensitivity compared with culture. In 
patients with culture-confirmed pulmonary TB, the sensitivity of AFB microscopy ranges 
from 22 to 80% [Kim et al., 1984]. In the setting of low income countries as elsewhere, there 
are a number of factors that influence the diagnosis of smear negative tuberculosis. These 
factors include the prevalence of tuberculosis in the population, the prevalence of HIV 
infection, and finally, the prevalence of other infections that may mimic tuberculosis. In 
under-resourced, over-worked TB control programmes, laboratories cannot cope with the 
influx of diagnostic and follow-up smear examinations, and smears may not be done at all. 
For example, in Botswana in 1992, 48% of patients reported with pulmonary tuberculosis 
had no smear examinations performed [De Cock and Wilkinson, 1995].  Alternatively, the 
sputum specimens collected may be inadequate in quality or number. Ipuge et al. [Ipuge et 
al., 1996] found that 83.4% of smear-positive cases were detected on the first specimen, 
12.2% on the second, and 4.4% on the third, by Ziehl-Neelsen staining under routine 
programme conditions in Tanzania. Finally, the performance of the smears may be 
technically inadequate. Declining quality of smear examination is a particular problem in 
www.intechopen.com
 
Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis 
 
138 
overburdened laboratories in HIV-endemic countries. When, as part of an epidemiological 
study of TB and HIV in Tanzania, Chum et al. [Chum et al., 1996] compared the sputum 
microscopy results obtained in local and reference laboratories, 29% of new smear-negative 
cases (on the basis of local microscopy) were found to be smear-positive by the reference 
laboratory. False-negative results can be due to inadequate staining, under- or over-
decolourisation, or inspection of too few fields (i.e., a minimum of 100 fields of a Ziehl-
Neelsen smear must be examined before reporting a negative result and this examination 
takes about 5–10 minutes) [WHO 1998].  
Other diseases identified in patients suspected of having TB include bacterial pneumonia 
due to a wide range of pathogens, Pneumocystis carinii pneumonia (PCP), Kaposi's 
sarcoma, nocardiosis and fungal infections with Cryptococcus neoformans and Aspergillus 
fumigatus. Bacterial pneumonia is the main differential diagnosis in HIV-positive and HIV-
negative individuals, while PCP, cryptococcosis, and nocardiosis are of increased 
importance in HIV-positive subjects. The reported rates of PCP in African HIV-positive 
patients with respiratory symptoms vary between 0 and 33%. [Abouya et al., 1992; Kamanfu 
et al., 1993; Batungwanayo et al., 1994; Greenberg et al., 1995; Malin et al., 1995; Daley et al., 
1996; Grant et al., 1998]. 
This variation has not been fully explained, but has been attributed to differences in patient 
selection, the level of immunodeficiency of HIV-positive patients in Africa, the limited 
availability of specialized laboratory diagnostics, the failure to diagnose PCP in the presence 
of multiple other infections, and geographic differences in the prevalence of PCP 
[Batungwanayo et al., 1994; Malin et al., 1995]. HIV-associated nocardiosis may also be 
under diagnosed. Lucas et al. [Lucas et al., 1994] conducted an autopsy study of 247 HIV-
positive cases in Abidjan, Ivory Coast, and found one case of nocardiosis for every nine TB 
cases. These medical conditions account for significant morbidity and mortality in patients 
presenting with ‘smear-negative pulmonary disease’ in HIV- and TB endemic developing 
countries. However, the pre-eminent position of TB as the major pathogen in these 
circumstances must be emphasised. Moreover, it is necessary to emphase the importance of 
appropriate diagnosis of smear negative tuberculosis, both in terms of public health to 
identify early infectious sources more rapidly, and in terms of individual health, to identify 
specific diseases that can be treated. "In areas of high prevalence of tuberculosis, the most 
common disease that occurs in someone with the clinical signs of tuberculosis but has a 
negative sputum smear is still tuberculosis 
7. Conclusion and future perspective 
Smear-negative pulmonary TB is an increasing clinical problem in developing countries 
affected by the dual HIV/TB epidemic. It is clear that in sub-Saharan Africa more 
information is required to help solve some of the problems surrounding the diagnosis of 
smear negative TB.  Clear diagnostic criteria need to be developed and agreed upon, and 
these may vary from country to country according to the availability of diagnostic facilities. 
Management algorithms that have been validated by local studies should improve case 
detection. Where current WHO guidelines have been implemented, clinical audits have the 
potential to improve the quality of diagnosis of smear-negative tuberculosis. Wider use of 
sputum induction and evaluation of novel sputum processing techniques may also improve 
the investigation of these patients. Some authors have argued for the wider availability of 
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TB culture facilities in developing countries; however, these Utopian interventions will 
require increased financial and technical support from the international community. The 
contribution of false negative sputum smears to the overall burden of smear-negative TB 
and the deficiencies in the system that lead to false-negative results need to be addressed. 
Rates of misdiagnosis of smear-negative tuberculosis can be reduced by development of 
diagnostic tools, which incorporate the diagnosis of other non-tuberculosis pulmonary 
disorders. Extensive basic research to develop rapid, simple, and accurate tuberculosis 
diagnostic tools that can be used in laboratories and remote locations is essential. Increased 
political commitment, greater scientific interest, and massive investment are needed. At the 
same time, innovative means need to be sought to address the human resources issues in the 
diagnosis problem, such as strategic efforts to train adequate and efficient laboratory staff at 
all levels. New diagnostic techniques are required in addition to AFB microscopy for the 
identification of smear-negative tuberculosis. These need to be appropriate for use in low 
income countries. Research into development of more cost-effective microbiological and 
serological diagnostic solutions is under way. However, until such tests are widely 
available, diagnostic scoring systems and algorithms must be developed and validated to 
assist clinicians working in resource-poor settings. Research collaboration is required 
between countries with similar HIV prevalence to address these research needs and to 
develop joint management guidelines, which can be applied and evaluated in different 
situations. 
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